VANCOUVER, British Columbia — December 1, 2025 — Leads & Copy — Rakovina Therapeutics Inc. (TSX-V: RKV) has secured consent from debenture holders to extend the maturity date of its 12.0% convertible debentures. The extension shifts the maturity date from November 29, 2025, to January 28, 2026.
Holders representing at least 66 2/3% of the outstanding principal of the convertible debentures have approved the extension. This action was formalized through a written consent on November 28, 2025, as per the terms of the debenture indenture dated May 29, 2023, between Rakovina and Odyssey Trust Company, the debenture trustee.
The company has decided not to proceed with other amendments that were previously mentioned in a news release on June 30, 2025. With the extension, Rakovina plans to execute a supplemental indenture with the Debenture Trustee to officially amend the indenture terms. The convertible debentures will maintain an interest rate of 12.0% during the extended period, and all other terms will remain unchanged.
The extension is still pending approval from the TSX Venture Exchange.
Several company directors have involvement in the extension, holding approximately $100,000 principal amount of the convertible debentures, which is about 6.9% of the total outstanding principal. Their participation is considered a related party transaction under Multilateral Instrument 61-101 and Exchange Policy 5.9. However, the company has utilized exemptions within MI 61-101, as the value of the debentures held by these related parties does not exceed 25% of Rakovina’s market capitalization.
Rakovina also announced the expiration of its early exercise warrant incentive program on September 2, 2025, with no warrants being exercised.
Rakovina Therapeutics Inc. is a biopharmaceutical company focused on innovative cancer treatments, utilizing AI-driven technologies such as Deep-Docking™ and Enki™ platforms to target DNA-damage response. Their goal is to advance drug candidates into clinical trials through collaborations with pharmaceutical partners.
Michelle Seltenrich, BSc MBA
Director, Corporate Development
IR@rakovinatherapeutics.com
778-773-5432
Source: Rakovina Therapeutics Inc.
